1. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy
- Author
-
Anastasia R. Goloudina, Elena Y. Kochetkova, Marc Bardou, Arlette Hammann, Oleg N. Demidov, Sarah Richaud, Carmen Garrido, Olga A. Fedorova, Nickolai A. Barlev, Burhan Uyanik, V Clausse, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Institute of Cytology of the Russian Academy of Science (St. Petersburg), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Fondation ARC, laboratoire d'excellence ARC, La Ligue Contre le Cancer CCIR-GE (14-15-00636 ), fondation scientifique russe, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), and UNICANCER
- Subjects
Wip1 ,Apoptosis ,Cell Cycle Proteins ,Pharmacology ,MESH: G2 Phase Cell Cycle Checkpoints ,Histones ,MESH : Phosphorylation ,Mice ,MESH : Cell Cycle Proteins ,MESH: Animals ,MESH: Tumor Suppressor Protein p53 ,MESH: Histones ,Kinase ,Tp53 mutations ,MESH : Mice, Transgenic ,3. Good health ,Protein Phosphatase 2C ,Survival Rate ,MESH : Antineoplastic Agents ,H2ax phosphorylation ,P53 activation ,MESH: Protein Phosphatase 2C ,RNA Interference ,MESH : Colorectal Neoplasms ,MESH : Carrier Proteins ,Histone H2ax ,MESH: Mitochondria ,Immunology ,Human fibroblasts ,MESH: Carrier Proteins ,Antineoplastic Agents ,MESH: Protein-Tyrosine Kinases ,MESH: Protein-Serine-Threonine Kinases ,MESH : Cisplatin ,03 medical and health sciences ,MESH: Cell Cycle Proteins ,Genotoxic stress ,MESH : Protein-Tyrosine Kinases ,Humans ,MESH : Histones ,Anticancer Therapy ,MESH: DNA Damage ,Cisplatin ,MESH: Humans ,MESH: Phosphorylation ,[ SDV.BC ] Life Sciences [q-bio]/Cellular Biology ,MESH : Humans ,MESH : Nuclear Proteins ,030104 developmental biology ,Cancer cell ,MESH: Antineoplastic Agents ,Carrier Proteins ,MESH: Nuclear Proteins ,MESH : Apoptosis ,Dna-damage response ,0301 basic medicine ,Cancer Research ,MESH: Caspase 3 ,MESH : Caspase 3 ,Phosphorylation ,Cytotoxicity ,MESH : DNA Damage ,Sensitization ,medicine.diagnostic_test ,Caspase 3 ,Nuclear Proteins ,Protein-Tyrosine Kinases ,MESH : Survival Rate ,Mitochondria ,G2 Phase Cell Cycle Checkpoints ,Wee1 ,medicine.anatomical_structure ,MESH : Protein Phosphatase 2C ,Original Article ,MESH : Mitochondria ,Colorectal Neoplasms ,medicine.drug ,MESH : Protein-Serine-Threonine Kinases ,MESH: Cell Line, Tumor ,MESH: Survival Rate ,MESH: Mice, Transgenic ,MESH: RNA Interference ,Phosphatase ,Mice, Transgenic ,[SDV.BC]Life Sciences [q-bio]/Cellular Biology ,Biology ,Protein Serine-Threonine Kinases ,Flow cytometry ,Cellular and Molecular Neuroscience ,Cell Line, Tumor ,MESH : Mice ,medicine ,Animals ,MESH: Mice ,MESH : Cell Line, Tumor ,MESH: Apoptosis ,Cell Biology ,MESH : Tumor Suppressor Protein p53 ,MESH: Cisplatin ,Cancer research ,biology.protein ,MESH : Animals ,MESH : G2 Phase Cell Cycle Checkpoints ,MESH : RNA Interference ,Tumor Suppressor Protein p53 ,MESH: Colorectal Neoplasms ,DNA Damage - Abstract
Inactivation of p53 found in more than half of human cancers is often associated with increased tumor resistance to anti-cancer therapy. We have previously shown that overexpression of the phosphatase Wip1 in p53-negative tumors sensitizes them to chemotherapeutic agents, while protecting normal tissues from the side effects of anti-cancer treatment. In this study, we decided to search for kinases that prevent Wip1-mediated sensitization of cancer cells, thereby interfering with efficacy of genotoxic anti-cancer drugs. To this end, we performed a flow cytometry-based screening in order to identify kinases that regulated the levels of γH2AX, which were used as readout. Another criterion of the screen was increased sensitivity of p53-negative tumor cells to cisplatin (CDDP) in a Wip1-dependent manner. We have found that a treatment with a low dose (75 nM) of MK-1775, a recently described specific chemical inhibitor of Wee1, decreases CDDP-induced H2AX phosphorylation in p53-negative cells and enhances the Wip1-sensitization of p53-negative tumors. We were able to reduce CDDP effective concentration by 40% with a combination of Wip1 overexpression and Wee1 kinase inhibition. We have observed that Wee1 inhibition potentiates Wip1-dependent tumor sensitization effect by reducing levels of Hipk2 kinase, a negative regulator of Wip1 pathway. In addition, during CDDP treatment, the combination of Wee1 inhibition and Wip1 overexpression has a mild but significant protective effect in normal cells and tissues. Our results indicate that inhibition of the negative regulators of Wip1 pathway, Wee1 and Hipk2, in p53-negative tumors could potentiate efficiency of chemotherapeutic agents without concomitant increase of cytotoxicity in normal tissues. The development and clinical use of Wee1 and Hipk1 kinase chemical inhibitors might be a promising strategy to improve anti-cancer therapy.
- Published
- 2016
- Full Text
- View/download PDF